Das kutane Plattenepithelkarzinom – ein Update

ZUSAMMENFASSUNG

Hintergrund Das kutane Plattenepithelkarzinom (PEK) ist nach dem Basalzellkarzinom der zweithäufigste bösartige Hauttumor. In Deutschland wurden 2014 über 50 000 PEK-Neuerkrankungen dokumentiert. Mit Zunahme der durchschnittlichen Lebenserwartung und Komorbiditäten treten mittlerweile auch gehäuft lokal fortgeschrittene Tumore mit Metastasierung auf.

Methode Selektive Literaturrecherche in PubMed und unter Berücksichtigung der deutschen S3-Leitlinien „Aktinische Keratosen und Plattenepithelkarzinom der Haut“ und „Prävention von Hautkrebs“.

Ergebnisse Beim PEK ist der Goldstandard die vollständige Exzision des Primärtumors mittels histopathologischer Kontrolle der Schnittränder. Eine Radiotherapie kann eingesetzt werden, wenn eine vollständige Exzision nicht erreicht werden kann bzw. Inoperabilität besteht. Im Falle eines metastasierten (mPEK) oder lokal fortgeschrittenen (laPEK) PEK, welches nicht kurativ operiert oder bestrahlt werden kann, werden systemische medikamentöse Therapien eingesetzt. Mit der Zulassung des PD1-Antikörpers Cemiplimab steht seit 2019 in der EU eine neue systemische Therapie zur Behandlung des fortgeschrittenen PEK zur Verfügung. Nach bis zu 3 Jahren Follow-up sprechen noch 46 % der Patienten mit mPEK und laPEK auf Cemiplimab an, der Medianwert für das Gesamtüberleben und die Ansprechdauer ist in beiden Gruppe noch nicht erreicht. Weitere Antikörper gegen PD1 oder PDL1, Kombinationstherapien sowie die Immuntherapie mit onkolytischen Viren ermöglichen zahlreiche Therapieoptionen und sind aktuell Gegenstand der Forschung.

Schlussfolgerung Mit der Zunahme von fortgeschrittenen Stadien des PEK nimmt die Wichtigkeit des interdisziplinären Tumorboards für den Therapieentscheid immer mehr zu. Die Weiterentwicklung bestehender therapeutischer Konzepte, die Identifikation von gut wirksamen Kombinationstherapien sowie die Entwicklung weiterer verträglicher zielgerichteter Systemtherapien ist eine entscheidende dermatoonkologische Herausforderung der nächsten Jahre.

ABSTRACT

Background The cutaneous squamous cell carcinoma (CSCC) is the second most common nonmelanoma skin cancer with an increasing incidence rate. Patients presenting with high-risk lesions associated with locally advanced or metastatic CSCC face high rates of recurrence and mortality.

Methods Selective literature review based on PubMed and consideration of current guidelines “Aktinische Keratosen und Plattenepithelkarzinom der Haut” and “Prävention von Hautkrebs”.

Findings Complete surgical excision with histopathological control of excision margins is the gold standard in the treatment of primary CSCC. Radiotherapy can be used as an alternative treatment of inoperable CSCCs. In 2019, the PD1-antibody cemiplimab, has been approved for the treatment of locally advanced and metastatic CSCC by the European Medicines Agency. After 3 years of follow up, Cemiplimab shows overall response rates of 46 %, the median overall survival and median response rate had not been reached yet. Additional immunotherapeutics, combinations with other agents and oncolytic viruses are all potentially worth study to try, so clinical trial data will be forthcoming over the next few years to guide optimal use of these agents.

Conclusion Multidisciplinary board decisions are mandatory for all patients with advanced disease who require more than surgery. Further development of existing therapeutic concepts, identification of new combination therapies and the development of new immunotherapeutics will be the key challenge over the next few years.

Schlüsselwörter

Plattenepithelkarzinom - Immuntherapie - Hautkrebs - Cemiplimab - Leitlinie

Keywords

Cutaneous squamous cell carcinoma - Cemiplimab - skin cancer - Anti-PD-1 antibody

Publication History

Article published online:
24 October 2022

• Literatur

• 1 Werner RN, Sammain A, Erdmann R. et al The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502-518 DOI: 10.1111/bjd.12420.
• 2 Leiter U, Keim U, Eigentler T. et al Incidence, mortality, and trends of nonmelanoma skin cancer in germany. J Invest Dermatol 2017; 137: 1860-1867 DOI: 10.1016/j.jid.2017.04.020.
• 3 Haisma MS, Plaat BEC, Bijl HP. et al Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol 2016; 75: 722-730 DOI: 10.1016/j.jaad.2016.06.010.
• 4 Deutsche Krebsgesellschaft DK. AWMF. S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut. Langversion 1.0 – Juni 2019 https://www.awmf.org/uploads/tx_szleitlinien/032-022OLl_S3_Aktinische_Keratosen-Plattenepithelkarzinom-PEK_2019-07.pdf 2019
• 5 Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010; 375: 673-685 DOI: 10.1016/S0140-6736(09)61196-X.
• 6 Dean NR, Sweeny L, Magnuson JS. et al Outcomes of recurrent head and neck cutaneous squamous cell carcinoma. J Skin Cancer 2011: 972497 DOI: 10.1155/2011/972497
• 7 Stratigos A, Garbe C, Lebbe C. et al Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 1989-2007 DOI: 10.1016/j.ejca.2015.06.110.
• 8 Chren MM, Linos E, Torres JS. et al Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013; 133: 1188-1196 DOI: 10.1038/jid.2012.403.
• 9 Breuninger H, Schaumburg-Lever G. Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohsʼ technique. J Pathol 1988; 154: 167-171 DOI: 10.1002/path.1711540209.
• 10 Thomas DJ, King AR, Peat BG. Excision margins for nonmelanotic skin cancer. Plast Reconstr Surg 2003; 112: 57-63 DOI: 10.1097/01. PRS.0000067479.77859.31.
• 11 Gutzmer R, Wiegand S, Kölbl O. et al Actinic keratosis and cutaneous squamous cell carcinoma. Dtsch Arztebl Int 2019; 116: 616-626 DOI: 10.3238/arztebl.2019.0616.
• 12 Warren TA, Panizza B, Porceddu SV. et al Outcomes after surgery and postoperative radiotherapy for perineural spread of head and neck cutaneous squamous cell carcinoma. Head Neck 2016; 38: 824-831 DOI: 10.1002/hed.23982.
• 13 Jambusaria-Pahlajani A, Miller CJ, Quon H. et al Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009; 35: 574-585 DOI: 10.1111/j.1524-4725.2009.01095.x.
• 14 Mendenhall WM, Amdur RJ, Hinerman RW. et al Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope 2009; 119: 1994-1999 DOI: 10.1002/lary.20608.
• 15 Kreuter A, van Eijk T, Lehmann P. et al Electrochemotherapy in advanced skin tumors and cutaneous metastases – a retrospective multicenter analysis. J Dtsch Dermatol Ges 2015; 13: 308-315 DOI: 10.1111/ddg.12583.
• 16 Campana LG, Testori A, Curatolo P. et al Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. Eur J Surg Oncol 2016; 42: 1914-1923 DOI: 10.1016/j.ejso.2016.06.399.
• 17 Bertino G, Sersa G, De Terlizzi F. et al European research on electrochemotherapy in head and neck cancer (EURECA) project: Results of the treatment of skin cancer. Eur J Cancer 2016; 63: 41-52 DOI: 10.1016/j.ejca.2016.05.001.
• 18 Allen JE, Stolle LB. Utility of sentinel node biopsy in patients with highrisk cutaneous squamous cell carcinoma. Eur J Surg Oncol 2015; 41: 197-200 DOI: 10.1016/j.ejso.2014.10.055.
• 19 Leiter U, Gutzmer R, Alter M. et al Cutaneous squamous cell carcinoma. Hautarzt 2016; 67: 857-866 DOI: 10.1007/s00105-016-3875-2.
• 20 Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection?. Dermatol Surg 2007; 33: 410-420 DOI: 10.1111/j.1524-4725.2007.33087.x.
• 21 Hillen U, Ulrich M, Alter M. et al Cutaneous squamous cell carcinoma: a review with consideration of special patient groups. Hautarzt 2014; 65: 590-599 DOI: 10.1007/s00105-013-2734-7.
• 22 Mendenhall WM, Amdur RJ, Hinerman RW. et al Skin cancer of the head and neck with perineural invasion. Am J Clin Oncol 2007; 30: 93-96 DOI: 10.1097/01.coc.0000251224.16075.60.
• 23 Tomaszewski JM, Gavriel H, Link E. et al Aggressive behavior of cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. Laryngoscope 2014; 124: 2043-2048 DOI: 10.1002/lary.24586.
• 24 Ulrich C, Arnold R, Frei U. et al Skin changes following organ transplantation: an interdisciplinary challenge. Dtsch Arztebl Int 2014; 111: 188-194 DOI: 10.3238/arztebl.2014.0188.
• 25 O’Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253-261 DOI: 10.1016/j.jaad.2010.11.062.
• 26 Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691 DOI: 10.1056/NEJMra022137.
• 27 Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17 DOI: 10.1067/mjd.2002.125579.
• 28 Alter M, Satzger I, Schrem H. et al Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Dtsch Dermatol Ges 2014; 12: 480-488 DOI: 10.1111/ddg.12355.
• 29 Teymoortash A, Schultz ES, Werner JA. Significance of parotid metastases of squamous cell carcinoma of scalp. Hautarzt 2007; 58: 323-327 DOI: 10.1007/s00105-006-1275-8.
• 30 Fujiwara M, Suzuki T, Takiguchi T. et al Evaluation of positron emission tomography imaging to detect lymph node metastases in patients with high-risk cutaneous squamous cell carcinoma. J Dermatol 2016; 43: 1314-1320 DOI: 10.1111/1346-8138.13403.
• 31 Gellrich FF, Hüning S, Beissert S. et al Medical treatment of advanced cutaneous squamous-cell carcinoma. J Eur Acad Dermatol Venereol 2019; 33 (Suppl. 08) 38-43 DOI: 10.1111/jdv.16024.
• 32 Behshad R, Garcia-Zuazaga J, Bordeaux JS. Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature. Br J Dermatol 2011; 165: 1169-1177 DOI: 10.1111/j.1365-2133.2011.10524.x.
• 33 Guminski A, Stein B. Immunotherapy and other systemic therapies for cutaneous SCC. Oral Oncol 2019; 99: 104459 DOI: 10.1016/j.oraloncology. 2019.104459.
• 34 Chen L, Aria AB, Silapunt S. et al Emerging nonsurgical therapies for locally advanced and metastatic nonmelanoma skin cancer. Dermatol Surg 2019; 45: 1-16 DOI: 10.1097/DSS.0000000000001601.
• 35 Foote MC, McGrath M, Guminski A. et al Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 2014; 25: 2047-2052 DOI: 10.1093/annonc/mdu368.
• 36 Rischin D, Migden MR, Lim AM. et al Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer 2020: 8 DOI: 10.1136/jitc-2020-000775
• 37 Hober C, Fredeau L, Pham Ledard A. et al Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience. Annals of Oncology 2020; 31: S737 DOI: 10.1016/j.annonc.2020.08.1210.
• 38 Hughes BGM, Munoz-Couselo E, Mortier L. et al Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629. Presented at: AACR Annual Meeting; April 10–15, 2021; Virtual. Abstract CT006
• 39 Grob JJ, Gonzalez R, Basset-Seguin N. et al Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase II trial (KEYNOTE-629). J Clin Oncol 2020; 38: 2916-2925 DOI: 10.1200/JCO.19.03054.
• 40 Eglmeier J, Debus D, Schultz ES. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia: a case series and literature review. Eur J Dermatol 2020; 30: 69-71 DOI: 10.1684/ejd.2020.3710.
• 41 Chul PJ, WL J, Keith F. et al Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis. Journal of Clinical Oncology 2018; 36: 9564-9564 DOI: 10.1200/JCO.2018.36.15_suppl.9564.
• 42 Leiter U, Loquai C, Reinhardt L. et al Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. J Immunother Cancer 2020: 8 DOI: 10.1136/jitc-2020-000897
• 43 Achard C, Surendran A, Wedge ME. et al Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine 2018; 31: 17-24 DOI: 10.1016/j.ebiom.2018.04.020.
• 44 Russell SJ, Barber GN. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 2018; 33: 599-605 DOI: 10.1016/j.ccell.2018.03.011.